Plaučių vėžio gydymas

1. Update 2025: Management of Non‑Small-Cell Lung Cancer. PubMed
2. Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment .... PubMed
3. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challen.... PubMed

4. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemothe.... PubMed
5. Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected .... PubMed
6. Association between time-to-treatment and outcomes in non-small cell lung can.... PubMed
7. Efficacy and safety of first-line carboplatin-versus cisplatin-based chemothe.... PubMed
8. Yin X et al. A meta-analysis of lentinan injection combined with chemotherapy in the treatment of nonsmall cell lung cancer. Indian journal of cancer. 2015. PubMed
9. Zhao C et al. Lentinan combined with cisplatin for the treatment of non-small cell lung cancer. Medicine. 2021. PubMed
10. Li M et al. Lentinan triggers oxidative stress-mediated anti-inflammatory responses in lung cancer cells. Molecular and cellular biochemistry. 2022. PubMed
11. Gui Y et al. Oridonin improves the therapeutic effect of lentinan on lung cancer. Experimental and therapeutic medicine. 2021. PubMed
12. Wang Y et al. Investigation on the efficiency of lentinan for injection combining cisplatin on treating malignant pleural effusion based on systematic review and meta-analysis. Medicine. 2024. PubMed
13. Song Z et al. Translational Nanotherapeutics Reprograms Immune Microenvironment in Malignant Pleural Effusion of Lung Adenocarcinoma. Advanced healthcare materials. 2021. PubMed
14. Congcong Q et al. Evaluation of Efficacy and Safety for Lentinan in the Control of the Malignant Pleural Effusions via Intrapleural Injection. The American journal of the medical sciences. 2019. PubMed
15. Ansell SM et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. The New England journal of medicine. 2015. PubMed
16. Goodman A et al. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nature reviews. Clinical oncology. 2017. PubMed
17. Zak J et al. JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma. Science (New York, N.Y.). 2024. PubMed
18. Chen H et al. Integrative spatial analysis reveals tumor heterogeneity and immune colony niche related to clinical outcomes in small cell lung cancer. Cancer cell. 2025. PubMed
19. Redin E et al. Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy. Cancer research. 2025. PubMed
20. Tani M et al. In vitro generation of activated natural killer cells and cytotoxic macrophages with lentinan. European journal of clinical pharmacology. 1992. PubMed
21. Hamano K et al. The preoperative administration of lentinan ameliorated the impairment of natural killer activity after cardiopulmonary bypass. International journal of immunopharmacology. 1999. PubMed
22. Mattiola I et al. The macrophage tetraspan MS4A4A enhances dectin-1-dependent NK cell-mediated resistance to metastasis. Nature immunology. 2019. PubMed
23. Chandrakesan P et al. DCLK1-Isoform2 Alternative Splice Variant Promotes Pancreatic Tumor Immunosuppressive M2-Macrophage Polarization. Molecular cancer therapeutics. 2020. PubMed
24. Fan TW et al. Polarization and β-Glucan Reprogram Immunomodulatory Metabolism in Human Macrophages and Ex Vivo in Human Lung Cancer Tissues. Journal of immunology (Baltimore, Md. : 1950). 2022. PubMed
25. Fang J et al. Structure of a β-glucan from Grifola frondosa and its antitumor effect by activating Dectin-1/Syk/NF-κB signaling. Glycoconjugate journal. 2012. PubMed
26. Zhang M et al. β-Glucan from Saccharomyces cerevisiae induces SBD-1 production in ovine ruminal epithelial cells via the Dectin-1-Syk-NF-κB signaling pathway. Cellular signalling. 2019. PubMed
27. Gringhuis SI et al. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation through Raf-1 and Syk. Nature immunology. 2009. PubMed
28. Ooshiro M et al. [Ten cases of advanced gastro-intestinal cancer that required preoperative dosage of PSK]. Gan to kagaku ryoho. Cancer & chemotherapy. 2009. PubMed
29. Maehara Y et al. Postoperative PSK and OK-432 immunochemotherapy for patients with gastric cancer. Cancer chemotherapy and pharmacology. 1993. PubMed
30. Ito G et al. Correlation between efficacy of PSK postoperative adjuvant immunochemotherapy for gastric cancer and expression of MHC class I. Experimental and therapeutic medicine. 2012. PubMed
31. Cheng J et al. The Promising Effects of Astaxanthin on Lung Diseases. Advances in nutrition (Bethesda, Md.). 2021. PubMed
32. Wu C et al. [Astaxanthin inhibits proliferation and promotes apoptosis of A549 lung cancer cells via blocking JAK1/STAT3 pathway]. Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology. 2016. PubMed
33. Qian J et al. Molecular mechanisms underlying the beneficial effects of Astaxanthin on metabolic changes in lung cancer and diabetes mellitus: A dual pathophysiological perspective. International immunopharmacology. 2025. PubMed
34. Park JS et al. Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans. Nutrition & metabolism. 2010. PubMed
35. Lee J et al. Anti-Oxidant and Anti-Inflammatory Effects of Astaxanthin on Gastrointestinal Diseases. International journal of molecular sciences. 2022. PubMed
36. Wang T et al. Astaxanthin protected against the adverse effects induced by diesel exhaust particulate matter via improving membrane stability and anti-oxidative property. Journal of hazardous materials. 2023. PubMed
37. Deng S et al. Lentinan inhibits tumor angiogenesis via interferon γ and in a T cell independent manner. Journal of experimental & clinical cancer research : CR. 2018. PubMed
38. Deng S et al. Correction to: Lentinan inhibits tumor angiogenesis via interferon γ and in a T cell independent manner. Journal of experimental & clinical cancer research : CR. 2021. PubMed
39. Wang H et al. Efficacy of biological response modifier lentinan with chemotherapy for advanced cancer: a meta-analysis. Cancer medicine. 2017. PubMed
40. Zhang Y et al. Lentinan as an immunotherapeutic for treating lung cancer: a review of 12 years clinical studies in China. Journal of cancer research and clinical oncology. 2018. PubMed
41. Wang XE et al. Immunomodulatory Effect of Lentinan on Aberrant T Subsets and Cytokines Profile in Non-small Cell Lung Cancer Patients. Pathology oncology research : POR. 2020. PubMed
42. Wang Y et al. Systematic review and meta-analysis on the efficacy and safety of Injectable Lentinan combined with chemotherapy in the treatment of gastric cancer. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2024. PubMed
43. Oba K et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer immunology, immunotherapy : CII. 2007. PubMed
44. Cheng SC et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science (New York, N.Y.). 2014. PubMed
45. Kidd P Astaxanthin, cell membrane nutrient with diverse clinical benefits and anti-aging potential. Alternative medicine review : a journal of clinical therapeutic. 2011. PubMed

Rodyti visus šaltinius (45)